Overview

Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain

Status:
Terminated
Trial end date:
2018-01-24
Target enrollment:
Participant gender:
Summary
Safety and pharmacokinetics of an abuse-deterrent, extended-release formulation of oxycodone hydrochloride with a sequestered naltrexone core in children 7-17 with moderate-severe pain.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Treatments:
Naltrexone
Oxycodone